CVS Health announces formulary and therapy strategy for PCSK9 inhibitors

CVS Health

23 November 2015 - CVS Health announced today that Repatha (evolocumab) from Amgen Inc. will be added as the only PCSK9 inhibitor on the CVS/caremark commercial formularies.

For more details, go to: https://www.cvshealth.com/content/cvs-health-announces-formulary-and-therapy-strategy-pcsk9-inhibitors

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Listing , Formulary